Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and M...

Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals (($MIST)) has held its Q1 earnings call. Read on for the main highlights of the call. Milestone Pharmaceuticals’ latest e...

Milestone Pharmaceuticals’ Earnings Call Highlights Early Launch Momentum

Singapore-based telecom firm Singtel ($SG:Z74) has signed a new deal with Mistral AI, a French private company backed by semiconductor giant ASML H...

Market Cap	$178.03M	P/E Ratio	N/A
52W High	$3.06	52W Low	$1.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	18.4%	52W Position	19.4%
Overall Score	25	Value Score	--
Quality Score	23	Technical Score	27

EPS Current Est	$-0.97	EPS Next Est	$-1.04
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$1.40	-0.71%	1.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIST	$1.40	-0.7%	1.27M
3
4
5
6

MIST

MIST

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Milestone Pharmaceuticals Inc. Data in Excel

Get Milestone Pharmaceuticals Inc. Data in Excel